Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Fiche publication
Date publication
septembre 2022
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ROYER Bernard, Pr SCHMITT Antonin
Tous les auteurs :
Maillard M, Launay M, Royer B, Guitton J, Gautier-Veyret E, Broutin S, Tron C, Le Louedec F, Ciccolini J, Richard D, Alarcan H, Haufroid V, Tafzi N, Schmitt A, Etienne-Grimaldi MC, Narjoz C, Thomas F,
Lien Pubmed
Résumé
Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidines (FP) administration in France. In this study, we aimed to refine the pre-analytical recommendations for determining U and dihydrouracil (UH ) concentrations, since they are essential in reliable DPD deficiency testing.
Mots clés
dihydropyrimidine dehydrogenase, dihydrouracil, intra-individual variability, pre-analytical practices, uracil
Référence
Br J Clin Pharmacol. 2022 09 14;: